Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

NCT02609737 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DEVICE: PET/CT Imaging
RADIATION: 68Ga-DOTA-JR11
RADIATION: 177Lu-DOTA-JR11

Sponsor

Memorial Sloan Kettering Cancer Center